AI assistant
Mirc Electronics Ltd — Report Publication Announcement 2026
May 22, 2026
62351_rns_2026-05-22_64fb08db-2560-4e10-a079-3a4858441156.pdf
Report Publication Announcement
Open in viewerOpens in your device viewer
ONIDA
OWNER'S PRIDE
22nd May, 2026
Ref. No. 23/2026-27
| To,
The Manager - Corporate Compliance
BSE Limited
25th Floor, P.J. Towers, Dalal Street,
Mumbai-400 001
Scrip Code: 500279 | To,
The Manager - Corporate Compliance
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MIRCELECTR |
| --- | --- |
Respected Sir/Madam,
Sub: Submission of Newspaper publication of extract of Audited Financial Results for the fourth quarter and year ended 31st March, 2026.
Ref: Regulations 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
In compliance with Regulation 30 and Regulation 47 read with Schedule III and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the extract of the Audited Financial Results for the fourth quarter and year ended 31st March, 2026 has been published by the Company on Friday, 22nd May, 2026 in the following newspapers:
- Financial Express (In English Language) and
- Navshakti (In Marathi Language)
You are requested to kindly take the same on record and oblige.
Thanking you.
for MIRC Electronics Limited
VIJAY JAIKRISHIN
MANSUKHANI
Digitally signed by VIJAY
JAIKRISHIN MANSUKHANI
Date: 2026.05.22 13:35:16 +05'30'
Vijay Mansukhani
Chairman & Managing Director
DIN: 01041809
MIRC ELECTRONICS LIMITED
Regd. Office: Onida House, G-1, M.I.D.C, Mahakali Caves Road, Andheri (East), Mumbai-400 093.
Tel.: +91-22-6697 5777
CIN No.: L32300MH1981PLC023637. Website: www.onida.com
FRIDAY, MAY 22, 2024
WWW.FINANCIALEXPRESS.COM
ONISA MIRC ELECTRONICS LIMITED
Pay from: Unrestricted
Sponsor: Unrestricted
Contact: 01-555-0000
E-mail: [email protected]
School of Industrial & Applied Financial Results for the Quarter 1 Year ended 31st March, 2024
| Particulars | Months' under $ | Year ended | ||
|---|---|---|---|---|
| 2018 | 2020 | 2018 | 2020 | |
| £000 | £000 | £000 | £000 | |
| Rate excess from gestation | 1,134.1 | 1,064.7 | 1,056 | 0.150 |
| Rate from 1 year for the period below the after 6/expansed and/or postparturian losses | 47,142 | 47,412 | 1,167 | 17,412 |
| Rate from 1 year for the period below the after 12/expansed and/or postparturian losses | 1,134.1 | 1,064.7 | 1,056 | 0.150 |
| Rate from 1 year for the period below the after 24/expansed and/or postparturian losses | 361.81 | 361.81 | 1,167 | 17,412 |
| Rate from 1 year for the period below the after 24/12/2024 | 1,095 | 1,009 | 1,011 | 0.150 |
| Rate from 12/12/2024 | 1,095 | 1,009 | 1,011 | 0.150 |
| Rate from 24/12/2024 | 1,095 | 1,009 | 1,011 | 0.150 |
1 - The above are added with deductive tax of standard income (less than the above) through cash (10% of the total) or other (less than the above) tax (10% of the total) in the following 3 years: 10% of the total, 10% of the total, and 10% of the total.
2 - The above includes the total tax (less than the above) on the tax rate included in the above column. The above column includes the tax rate included in the column, which includes the tax rate included in the column, which includes the tax rate included in the column and which includes the tax rate included in the column.
3 - The above includes an annual tax (less than the above) on the tax rate included in the column, which includes the tax rate included in the column, which includes the tax rate included in the column.
4 - The above includes the tax rate included in the column, which includes the tax rate included in the column.

MOSCHP
MOSCHP TECHNOLOGIES LIMITED
City of North Carolina, North Carolina
Regd Office: 7th Floor, 16th Street, Nylos / Hyderabad / Knowledge City, Hyderabad - 50000
Tel: 70 40 85230230
Email: [email protected]
www.moschp.com
STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2024
| Particulars | Quarter ended | Year ended | ||||
|---|---|---|---|---|---|---|
| 31-Mar-21 | 31-Dec-21 | 31-Mar-21 | 31-Dec-21 | 31-Mar-21 | 31-Dec-21 | |
| Actual | Unrealized | Actual | Actual | Actual | Actual | |
| Rate (in millions) | 15,954.09 | 15,083.02 | 13,492.24 | 99,062.94 | 47,956.82 | |
| Rate (in millions) | 471.13 | 5162.24 | 470.97 | 4,158.10 | 3,354.76 | |
| Net profit for the period 1 year (before tax and after exceptional item) | 471.13 | 870.28 | 870.97 | 3,276.24 | 3,354.76 | |
| Net profit for the period 1 year (after tax and exceptional item) | 794.54 | 430.27 | 870.82 | 3,525.43 | 3,226.70 | |
| Net cash for the period for the period 1 year (consuming profit for the period 1 year (after tax) and after comprehensive income after tax) | 1,103.78 | 227.43 | 768.52 | 2,768.46 | 3,108.34 | |
| Courts Share Capital | 3,872.00 | 5,692.27 | 3,877.82 | 3,873.38 | 3,877.82 | |
| Other equity (excluding revaluation reserve) (Carnitax 2018-2020) | 26,964.02 | 34,347.14 | 28,666.16 | 36,966.02 | 28,666.16 | |
| Basic earnings per share of Rs.2/- each | 0.41 | 0.23 | 0.46 | 1.59 | 1.76 | |
| Diluted earnings per share of Rs.2/- each | 0.41 | 0.21 | 0.45 | 1.76 | 1.75 |
1 - The above is an added full deductible tax (less than the above) on the tax rate included in the column. The above column includes the tax rate included in the column.

Key numbers of Standalone Financial Results
| Particulars | Quarter Ended | Year Ended | ||
|---|---|---|---|---|
| 31-Mar-21 | 31-Dec-21 | 31-Mar-21 | 31-Dec-21 | |
| Total income from operations | 14,211.22 | 13,546.97 | 12,223.37 | 32,613.45 |
| Net profit for the period 1 year (before tax and | 543.42 | 668.70 | 633.77 | 2,067.70 |
| Net profit for the period 1 year (after tax and | 543.42 | 293.99 | 630.77 | 2,465.26 |
| Investment for the period 1 year (after tax and | 0.22 | 0.22 | 0.22 | 0.22 |
| Consolidated | 227.04 | 203.34 | 218.51 | 2,362.92 |
1 - The above is an added form the Audited Consolidated and Standalone Financial Results for the Quarter and Year Ended 31 March 2025 that with the Stock Exchange under Regulator (3 of the S&S) Lustig (Volgates and Discount Requirements Regulators, 2010). The S&S is based on the Audited Consolidated and Standalone Financial Results for the Quarter of Company's website www.miscifan.com and NSSSDD website. (only code MSSD4P032407)
2 - The Audited Consolidated and Standalone Financial Results are reported in accordance with the Indian Accounting Standards (Ind-02) as prescribed under Section 122 of the Companies Act, 2013 (The ACT now with relevant rules thereunder, after accounting principal generally accepted in India and regulations issued by the International Exchange Commission).
3 - The Audited Consolidated and Standalone Financial Results are reported in accordance with the Indian Accounting Standards (Ind-02) as prescribed under Section 122 of the Companies Act, 2013 (The ACT now with relevant rules thereunder, after accounting principal generally accepted in India and regulations issued by the International Exchange Commission).
4 - The Audited Consolidated and Standalone Financial Results are reported in accordance with the other Accounting Standards (Ind-02) as prescribed under Section 122 of the Companies Act, 2013 (The ACT now with relevant rules thereunder, after accounting principal generally accepted in India and regulations issued by the International Exchange Commission).
P3
| Particulars | Quarter Ended | |||
|---|---|---|---|---|
| 31-Mar-21 | 31-Dec-21 | 31-Mar-21 | 31-Dec-21 | |
| Total income from operations | 14,211.22 | 13,546.97 | 12,223.37 | 32,613.45 |
| Net profit for the period 1 year (before tax and | 543.42 | 668.70 | 633.77 | 2,067.70 |
| Net profit for the period 1 year (after tax and | 543.42 | 293.99 | 630.77 | 2,465.26 |
| Consolidated | 227.04 | 203.34 | 218.51 | 2,362.92 |
1 - The above is an added form the Audited Consolidated and Standalone Financial Results for the Quarter and Year Ended 31 March 2025 that with the Stock Exchange under Regulator (3 of the S&S) Lustig (Volgates and Discount Requirements Regulators, 2010). The S&S is based on the Audited Consolidated and Standalone Financial Results for the Quarter and year ended March 31, 2025, reexamined. The full form of the Quarterly and Yearly Consolidated and Standalone Financial Results along with Limited Receipts, Audits Report from the International Exchange Commission (the International Exchange Commission) and the International Exchange Commission (the International Exchange Commission) are shown on the left.
| Particulars | Quarter Ended | |||
|---|---|---|---|---|
| 31-Mar-21 | 31-Dec-21 | 31-Mar-21 | 31-Dec-21 | |
| Total income from operations | 14,211.22 | 13,546.97 | 12,223.37 | 32,613.45 |
| Net profit for the period 1 year (before tax and | 5,410.00 | 17,246.37 | 12,223.37 | 3,880.31 |
| Net profit for the period 1 year (after tax and | 5,410.00 | 17,246.37 | 12,223.37 | 3,880.31 |
| Consolidated | 2,209.18 | 18,283.22 | 9,598.97 | 17,120.42 |
| Total | 1,004.00 | 1,004.00 | 1,004.00 | 1,004.00 |
1 - The above is an added form the Audited Consolidated and Standalone Financial Results for the Quarter and Year Ended 31 March 2025 that with the Stock Exchange under Regulator (3 of the Stock Exchange under Accounting Standard, Note 2010).
| Particulars | Quarter Ended | |||
|---|---|---|---|---|
| 31-Mar-21 | 31-Dec-21 | 31-Mar-21 | 31-Dec-21 | |
| Total income from operations | 1,004.00 | 1,004.00 | 1,004.00 | 1,004.00 |
| Net profit for the period 1 year (before tax and | 7,279.79 | 25,736.36 | 7,405.77 | 23,597.04 |
| Net profit for the period 1 year (after tax and | 7,279.79 | 25,644.53 | 7,405.77 | 23,597.04 |
| Net cash for the period 1 year (after tax and | 7,279.79 | 25,644.53 | 7,405.77 | 23,597.04 |
| Net cash in the period after tax | 3,209.08 | 18,283.22 | 9,598.97 | 17,120.42 |
| Total | 1,004.00 | 1,004.00 | 1,004.00 | 1,004.00 |
| 1 - The above is an added form the Audited Consolidated and Standalone Financial Results for the Quarter and Year Ended 31 March 2025 that with the Stock Exchange under Regulator (3 of the S&S) Lustig (Volgates and Discount Requirements Regulators, 2010). The S&S is based on the Audited Consolidated and Standalone Financial Results for the Quarter and year ended March 31, 2025, reexamined. The full form of the Quarterly and Yearly Consolidated and Standalone Financial Results along with Limited Receipts, Audits Report from the International Exchange Commission (the International Exchange Commission) are shown on the left. | 1,004.00 | 1,004.00 | 1,004.00 | 1,004.00 |
1 - The above is an added form the Audited Consolidated and Standalone Financial Results for the Quarter and Year ended March 31, 2025, reexamined. The full form of the Quarterly and Yearly Consolidated and Standalone Financial Results for the Quarter and year ended March 31, 2025, reexamined.
| Particulars | Quarter Ended | |||
|---|---|---|---|---|
| 31-Mar-21 | 31-Dec-21 | 31-Mar-21 | 31-Dec-21 | |
| Total income from operations | 1,004.00 | 1,004.00 | 1,004.00 | 1,004.00 |
| Net profit for the period 1 year (before tax and | 5,410.00 | 17,246.37 | 12,223.37 | 32,613.45 |
| Net profit for the period 1 year (after tax and | 5,410.00 | 17,246.37 | 12,223.37 | 32,613.45 |
| Net cash in the period after tax | 0.22 | 0.22 | 0.22 | 0.22 |
NOTICE
Syngene
Syngene International Limited
Regd. Office: Boxon SEZ, Boxon Park, Pte No. 2 & 3, Bommersentis Industrial Area,
31 Phase, Open Link Road, Bengtens - 560 098
CIN: L00119641960PLC014037, Email: [email protected]
Website: www.syngeneinf.com, Phone: 083 - 8901 9101
NOTICE: TRANSFER OF EQUITY SHARES OF THE COMPANY TO THE INTERIOR OPPORTUNITY AND PROTECTIVE FUND
The first time the Company (10% of its total purchase) to buy production services (10% of the Company's total) in 2013 (10% of its total purchase) was the first time the Company had purchased. The Company's stock exchange rate (10% of its total purchase) was 100%. The stock exchange rate for production services was 100%. The Company's stock exchange rate for production services was 100%. The Company's stock exchange rate for production services was 100%. The Company's stock exchange rate for production services was 100%. The Company's stock exchange rate for production services was 100%. The Company's stock exchange rate for production services was 100%.
The Company's website at https://www.cins.in/tnwsb/Inflation/index?barname=P366N3336L0032L01

NOTICE
Syngene
1999
1999
1999
1999
1999
1999
1999
1999
1999
1999
1999
1999
1999
1999
1999
चश्मी, शुक्रवार, 35 से 385
मातृ शक्ति
45
चालित सूचना
मातृ शक्तियां 4 वर्षीय दुनियाभरीय हिन्दी, भारत, पाकिस्तान आदि किसी दुनियाभरीय भाषा में "एक चश्मी" (संस्कृत "चश्मा") कहलाता है। यह शब्द हिमालयन भाषा है। यह शब्द "चश्मी" शब्द से भी जाना जाता है।
चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है
चालित सूचना
चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ है चश्मी का अर्थ
चिकित्सा
चश्मी का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ है चिकित्सा का अर्थ है चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ है चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ है चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ है चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ है चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ
चिकित्सा
चिकित्सा का अर्थ
चिकित्सा
चिकित्सा
चिकित्सा
चिकित्सा
चिकित्सा
चिकित्सा
चिकित्सा
चिकित्सा
चिकित्सा
चिकित्सा